6 slides generated from the cancer page, with a quiz from the open benchmark and speaker notes that cite the sources. Arrow keys move between slides; Print gives one slide per page.
Within triple-negative breast cancer, BL1 is a research RNA pattern linked to cell division and DNA-damage responses. It is different from a test showing failed DNA repair or benefit from a particular drug.
In Lehmann's 2011 analysis, BL1 was an expression cluster enriched for cell-cycle and DNA-damage-response programmes; representative cell models showed preferential cisplatin sensitivity. Enrichment for a response programme does not itself prove a functional repair defect. The 2016 TNBCtype-4 refinement retained BL1 as one of four tumour-focused profiles.
Across five historical neoadjuvant datasets, the 2016 report found pathological complete response in 41 percent of BL1 cases (95 percent confidence interval 33 to 51), 18 percent of BL2 (9 to 28) and 29 percent of LAR (17 to 41). Masuda's separate retrospective study included 146 profiled TNBCs, with 130 receiving standard neoadjuvant therapy and having evaluable response; BL1 had a 52 percent pCR rate there. These datasets do not supply a universal response probability.
| Setting | Approach | Guideline |
|---|---|---|
| Stage II to III | As for triple-negative disease: pembrolizumab with carboplatin and paclitaxel then an anthracycline before surgery (KEYNOTE-522); the subtype is not used to choose treatment. | not mapped |